Patiromer (Veltassa)

Indications

  • Hyperkalemia (see Hyperkalemia, [[Hyperkalemia]]): FDA-approved for this indication in 10/15
    • Hyperkalemia in the Setting of Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors

Pharmacology

  • Non-Absorbable Potassium Binder: takes hours-days

Metabolism

  • xxxx

Administration

  • xxxx

Dose Adjustment

  • Hepatic:
  • Renal:

Adverse Effects

Other Adverse Effects

  • xxx
  • xxx
  • xxx

References

  • Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors. N Engl J Med. 2015 Jan 15;372(3):211-21. doi: 10.1056/NEJMoa1410853. Epub 2014 Nov 21. [MEDLINE]